Page last updated: 2024-12-10

bruceantin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
BruceagenusA plant genus of the family SIMAROUBACEAE. Members contain bruceosides and bruceanols (quassinoids). The astringent seeds have been used to treat dysentery in southeastern Asia.[MeSH]SimaroubaceaeA plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida. Leaves are alternate and compound. Most have small flowers, bitter bark, and fleshy fruits that are sometimes winged. Members contain QUASSINS.[MeSH]

Cross-References

ID SourceID
PubMed CID5281304
CHEMBL ID509895
CHEBI ID3188
SCHEMBL ID16742407
MeSH IDM0043202

Synonyms (31)

Synonym
picras-3-en-21-oic acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxo-, methyl ester, (11beta,12alpha,15beta(e))-
41451-75-6
bruceantin ,
C08749
mls002703020 ,
picras-3-en-21-oic acid,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxo-, methyl ester, [11.beta.,12.alpha.,15.beta.(e)]-
nsc 165563
nsc165563 ,
2h-3,1-bc]pyran, picras-3-en-21-oic acid deriv.
picras-3-en-21-oic acid,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxo-, methyl ester, (11.beta.,12.alpha.,15.beta.(e))-
nsc-165563
picras-3-en-21-oic acid,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxo-, methyl ester [11.beta.,12.alpha.,15.beta.(e]-
chebi:3188 ,
bruceantine
CHEMBL509895
s3nw88di4t ,
unii-s3nw88di4t
bruceantin [mi]
nci-165563
picras-3-en-21-oic acid, 15-(((2e)-3,4-dimethyl-1-oxo-2-penten-1-yl)oxy)-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxo-, methyl ester, (11.beta.,12.alpha.,15.beta.)-
HY-N0840
IRQXZTBHNKVIRL-GOTQHHPNSA-N
SCHEMBL16742407
bruceantin(nsc165563)
mfcd00866510
Q27105979
methyl (1r,2s,3r,6r,8r,13s,14r,15r,16s,17s)-3-[(e)-3,4-dimethylpent-2-enoyl]oxy-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate
MS-30048
picras-3-en-21-oic acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxo-, methyl ester, (11beta,12alpha,15beta(e))- (9ci)
A873054
2h-3,11c-(epoxymethano)phenanthro[10,1-bc]pyran, picras-3-en-21-oic acid deriv

Research Excerpts

Overview

Bruceantin (BCT) is a natural product previously demonstrated to inhibit the growth of MM in RPMI 8226 cells-inoculated mouse xenograft models. It has also been shown to cause regression in already established tumors.

ExcerptReferenceRelevance
"Bruceantin (BCT) is a natural product previously demonstrated to inhibit the growth of MM in RPMI 8226 cells-inoculated mouse xenograft models, and to cause regression in already established tumors."( Bruceantin inhibits multiple myeloma cancer stem cell proliferation.
Berndt, S; Carpentier, G; Cuendet, M; Issa, ME; Pezzuto, JM, 2016
)
2.6

Effects

Bruceantin has been shown to induce cell differentiation in a number of leukemia and lymphoma cell lines. It has only limited activity against malignant melanoma.

ExcerptReferenceRelevance
"Bruceantin has been shown to induce cell differentiation in a number of leukemia and lymphoma cell lines. "( Multiple myeloma regression mediated by bruceantin.
Christov, K; Cuendet, M; Deng, Y; Hedayat, S; Helson, L; Lantvit, DD; McChesney, JD; Pezzuto, JM, 2004
)
2.03
"Bruceantin has only limited activity against malignant melanoma and is unlikely to contribute to systemic therapy of this disease, either as a single agent or in combinations of cytotoxic drugs."( A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma.
Arseneau, JC; Kuperminc, M; Ruckdeschel, JC; Wolter, JM, 1983
)
1.31

Treatment

ExcerptReferenceRelevance
"Bruceantin treatment (2.5-5 mg/kg) resulted in a significant regression of tumors without overt toxicity."( Multiple myeloma regression mediated by bruceantin.
Christov, K; Cuendet, M; Deng, Y; Hedayat, S; Helson, L; Lantvit, DD; McChesney, JD; Pezzuto, JM, 2004
)
1.31

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" These results demonstrated the importance of the effects of liver dysfunction on drug disposition and showed that the dosage should be reduced in patients with hepatic dysfunction."( Clinical pharmacology of bruceantin by radioimmunoassay.
Bedikian, A; Benjamin, RS; Bodey, GP; Brown, NS; Fong, KL; Ho, DH; Kramer, W; Wiseman, CL; Yap, BS, 1982
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.06580.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency0.06580.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)514.00000.00002.015110.0000AID240619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID399587Cytotoxicity against human Kasumi-1 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID358632Inhibition of DMBA-induced preneoplastic lesion formation in a BALB/c mouse mammary organ culture at 2 uM pretreated for 10 days before DMBA-challenge measured after 14 days2001Journal of natural products, Dec, Volume: 64, Issue:12
Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture.
AID399594Induction of apoptosis in human NCI-H929 cells after 24 hrs by DAPI staining2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID358628Antiproliferative activity against human HL60 cells assessed as inhibition of [3H]thymidine incorporation after 4 days by liquid scintillation counter2001Journal of natural products, Dec, Volume: 64, Issue:12
Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture.
AID1707241Antiproliferative activity against human HT-29 cells2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID399586Cytotoxicity against human HL60 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID358629Induction of cell differentiation in human HL60 cells assessed as superoxide anion production after 4 days by NBT reduction assay2001Journal of natural products, Dec, Volume: 64, Issue:12
Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture.
AID422119Growth inhibition of human NCI60 cells2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID422099Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID399582Cytotoxicity against human BV173 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID399592Induction of apoptosis in human RPMI8226 cells after 24 hrs by DAPI staining2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID422117Inhibition of protein synthesis in cell-free extract of mouse Krebs2 cells by SDS-PAGE2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID399589Cytotoxicity against human K562 cells assessed as cell viability at 50 ng/mL after 4 days by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID399584Cytotoxicity against human U937 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID399581Cytotoxicity against human SUP-B13 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID399593Induction of apoptosis in human U266 cells after 24 hrs by DAPI staining2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID358631Selectivity index, ratio of cytotoxic IC50 to antiproliferative IC50 for human HL60 cells2001Journal of natural products, Dec, Volume: 64, Issue:12
Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture.
AID417079Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivity-guided isolation of cytotoxic constituents of Brucea javanica collected in Vietnam.
AID1707242Antiproliferative activity against human HeLa cells2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID399591Induction of apoptosis in human HL60 cells after 24 hrs by DAPI staining2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID504257Reduction of mammary gland ductal branching in BRAC1/p53-deficient C57BL/6/129/Sv mouse model at 0.1 mg/kg, ip daily for 5 days measured post last dose by immunohistochemistry2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent.
AID417078Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivity-guided isolation of cytotoxic constituents of Brucea javanica collected in Vietnam.
AID399595Antitumor activity in human RPMI8226 cells xenografted in SCID mouse assessed as induction of apoptosis in peripheral proliferating areas at 5 to 12 mg mg/kg, ip administered every 3 days2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID240619Inhibitory concentration against cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID399590Cytotoxicity against concanavalin-stimulated human lymphocytes cells assessed as cell viability at 50 ng/mL after 4 days by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID399588Cytotoxicity against human REH cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID399583Cytotoxicity against human NB4 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID358633Toxicity in BALB/c mouse mammary organ culture assessed as morphological changes in mammary gland at 2 uM after 10 days2001Journal of natural products, Dec, Volume: 64, Issue:12
Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture.
AID399579Cytotoxicity against human Daudi cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID417082Ratio ED50 for human MCF7 cells to ED50 for human MCF7 cells in presence of 43 uM (-)-hydnocarpin2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivity-guided isolation of cytotoxic constituents of Brucea javanica collected in Vietnam.
AID399580Cytotoxicity against human RS4:11 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID422118Inhibition of protein synthesis in human HeLa cells assessed as [35S]methionine incorporation into protein treated for 45 mins before [35S]methionine addition by Whatman paper analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID504256Reduction of mammary gland ductal branching in BRAC1/p53-deficient C57BL/6/129/Sv mouse model at 0.1 mg/kg, ip daily for 7 days measured post last dose by immunohistochemistry2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent.
AID417080Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivity-guided isolation of cytotoxic constituents of Brucea javanica collected in Vietnam.
AID417081Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Bioactivity-guided isolation of cytotoxic constituents of Brucea javanica collected in Vietnam.
AID397122Inhibition of HIV1 RT
AID337702Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected human erythrocytes assessed by [3H]hypoxanthine uptake
AID333842Cytotoxicity against human KB cells
AID399585Cytotoxicity against human DHL6 cells by trypan blue exclusion method2004Journal of natural products, Feb, Volume: 67, Issue:2
Antitumor activity of bruceantin: an old drug with new promise.
AID358630Cytotoxicity against human HL60 cells assessed as loss of membrane integrity after 4 days by trypan blue exclusion assay2001Journal of natural products, Dec, Volume: 64, Issue:12
Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (42.86)18.7374
1990's2 (5.71)18.2507
2000's9 (25.71)29.6817
2010's6 (17.14)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.50 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]